View in EDS PDF Full Text

Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.

Saved in:
Bibliographic Details
Title: Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
Authors: Shah MH; Ohio State University College of Medicine, Columbus, OH, 43210, USA., Lorigan P; University of Manchester/Christie NHS Foundation Trust, Manchester, M20 4BX, UK., O'Brien ME; Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK., Fossella FV; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA., Moore KN; University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA., Bhatia S; Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA., Kirby M; ImmunoGen, Inc., Waltham, MA, 02451, USA., Woll PJ; Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Road, Sheffield, S10 2SJ, UK. p.j.woll@sheffield.ac.uk.
Source: Investigational new drugs [Invest New Drugs] 2016 Jun; Vol. 34 (3), pp. 290-9. Date of Electronic Publication: 2016 Mar 09.
Publication Type: Clinical Trial, Phase I; Journal Article; Multicenter Study
Journal Info: Publisher: Springer Country of Publication: United States NLM ID: 8309330 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1573-0646 (Electronic) Linking ISSN: 01676997 NLM ISO Abbreviation: Invest New Drugs Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Links:
  – Type: pdflink
Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 26961907
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Shah+MH%22">Shah MH</searchLink>; Ohio State University College of Medicine, Columbus, OH, 43210, USA.<br /><searchLink fieldCode="AU" term="%22Lorigan+P%22">Lorigan P</searchLink>; University of Manchester/Christie NHS Foundation Trust, Manchester, M20 4BX, UK.<br /><searchLink fieldCode="AU" term="%22O'Brien+ME%22">O'Brien ME</searchLink>; Royal Marsden Hospital, Sutton, Surrey, SM2 5PT, UK.<br /><searchLink fieldCode="AU" term="%22Fossella+FV%22">Fossella FV</searchLink>; Department of Thoracic/Head and Neck Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA.<br /><searchLink fieldCode="AU" term="%22Moore+KN%22">Moore KN</searchLink>; University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73104, USA.<br /><searchLink fieldCode="AU" term="%22Bhatia+S%22">Bhatia S</searchLink>; Department of Medicine, University of Washington School of Medicine and Fred Hutchinson Cancer Research Center, Seattle, WA, 98109, USA.<br /><searchLink fieldCode="AU" term="%22Kirby+M%22">Kirby M</searchLink>; ImmunoGen, Inc., Waltham, MA, 02451, USA.<br /><searchLink fieldCode="AU" term="%22Woll+PJ%22">Woll PJ</searchLink>; Academic Unit of Clinical Oncology, Weston Park Hospital, University of Sheffield, Whitham Road, Sheffield, S10 2SJ, UK. p.j.woll@sheffield.ac.uk.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309330%22">Investigational new drugs</searchLink> [Invest New Drugs] 2016 Jun; Vol. 34 (3), pp. 290-9. <i>Date of Electronic Publication: </i>2016 Mar 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase I; Journal Article; Multicenter Study
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Springer%22">Springer </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309330 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1573-0646 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2201676997%22">01676997 </searchLink><i>NLM ISO Abbreviation: </i>Invest New Drugs <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=26961907
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1007/s10637-016-0336-9
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 290
    Titles:
      – TitleFull: Phase I study of IMGN901, a CD56-targeting antibody-drug conjugate, in patients with CD56-positive solid tumors.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Shah MH
      – PersonEntity:
          Name:
            NameFull: Lorigan P
      – PersonEntity:
          Name:
            NameFull: O'Brien ME
      – PersonEntity:
          Name:
            NameFull: Fossella FV
      – PersonEntity:
          Name:
            NameFull: Moore KN
      – PersonEntity:
          Name:
            NameFull: Bhatia S
      – PersonEntity:
          Name:
            NameFull: Kirby M
      – PersonEntity:
          Name:
            NameFull: Woll PJ
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 06
              Text: 2016 Jun
              Type: published
              Y: 2016
          Identifiers:
            – Type: issn-electronic
              Value: 1573-0646
          Numbering:
            – Type: volume
              Value: 34
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: Investigational new drugs
              Type: main
ResultId 1